Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th>Citation</th>
<th>Fröse, Julia et al. “Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling.” Cell Reports 24, 4 (July 2018): 962–972 © 2018 The Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.celrep.2018.06.092">http://dx.doi.org/10.1016/j.celrep.2018.06.092</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sat Nov 24 04:22:12 EST 2018</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/117670">http://hdl.handle.net/1721.1/117670</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Creative Commons Attribution-NonCommercial-NoDerivs License</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a></td>
</tr>
</tbody>
</table>
Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling

Graphical Abstract

Highlights
- Activation of an EMT in carcinoma cells increases their extravasation efficiency
- The EMT-induced protein podocalyxin (PODXL) is a mediator of extravasation
- PODXL promotes extravasation through direct interaction with ezrin
- Ezrin orchestrates cortical polarization in extravasating cancer cells

Authors
Julia Fröse, Michelle B. Chen, Katie E. Hebron, ..., Andries Zijlstra, Roger D. Kamm, Robert A. Weinberg

Correspondence
weinberg@wi.mit.edu

In Brief
Fröse et al. investigate the influence of the EMT program on extravasation by applying diverse experimental tools to visualize and quantify this highly dynamic process. They discover that the EMT-induced protein podocalyxin (PODXL) promotes extravasation through direct interaction with the cytoskeletal linker protein ezrin.

Data and Software Availability
GSE74883
Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling

Julia Fröse,1,2 Michelle B. Chen,3 Katie E. Hebron,4 Ferenc Reinhardt,1 Cynthia Hajal,3 Andries Zijlstra,5,6 Roger D. Kamm,3,7 and Robert A. Weinberg1,8,9,10,*
1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
2Faculty of Biosciences, University of Heidelberg, 69117 Heidelberg, Germany
3Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
4Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA
5Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232, USA
6Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA
7Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
8Ludwig/MIT Center for Molecular Oncology, Cambridge, MA 02142, USA
9Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
10Lead Contact
*Correspondence: weinberg@wi.mit.edu
https://doi.org/10.1016/j.celrep.2018.06.092

SUMMARY

The epithelial-mesenchymal transition (EMT) endows carcinoma cells with traits needed to complete many of the steps leading to metastasis formation, but its contributions specifically to the late step of extravasation remain understudied. We find that breast cancer cells that have undergone an EMT extravasate more efficiently from blood vessels both in vitro and in vivo. Analysis of gene expression changes associated with the EMT program led to the identification of an EMT-induced cell-surface protein, podocalyxin (PODXL), as a key mediator of extravasation in mesenchymal breast and pancreatic carcinoma cells. PODXL promotes extravasation through direct interaction of its intracellular domain with the cytoskeletal linker protein ezrin. Ezrin proceeds to establish dorsal cortical polarity, enabling the transition of cancer cells from a non-polarized, rounded cell morphology to an invasive extravasation-competent shape. Hence, the EMT program can directly enhance the efficiency of extravasation and subsequent metastasis formation through a PODXL-ezrin signaling axis.

INTRODUCTION

Metastasis accounts for more than 90% of all cancer-related death, yet the mechanisms underlying this process remain incompletely understood (Lambert et al., 2017). In order to metastasize, cancer cells need to complete a series of distinct steps, including invasion into the stroma surrounding the primary tumor, entry into the lumina of blood vessels, survival in the circulation, extravasation from the vasculature, formation of micrometastases, and finally proliferation within the microenvironment of a distant organ leading to the formation of macroscopic metastases (Fidler, 2002). Carcinoma cells can acquire many of the traits needed to complete this cascade by undergoing an epithelial-mesenchymal transition (EMT) (Thiery et al., 2009). A number of studies have focused on the role of the EMT program in invasion and intravasation into blood vessels (Boyer and Thiery, 1993). Recent studies from our lab also suggest a role for this program in the post-extravasation proliferation of disseminated cancer cells and the outgrowth of micrometastases, the latter process termed metastatic colonization (De Cock et al., 2016; Shibue et al., 2013). In contrast, little is known about the role of the EMT program and its molecular mechanisms specifically during extravasation. Evidence suggesting a contribution of EMT to extravasation is fragmentary and largely correlative (Labelle et al., 2011; Stoletov et al., 2010; Yadavalli et al., 2017).

In the present study we describe the influence of the EMT program on extravasation by applying diverse experimental tools to visualize and quantify this highly dynamic process. We observe epithelial and mesenchymal breast cancer cells in high spatiotemporal resolution using the chick chorioallantoic membrane (CAM) and an in vitro microvascular network platform and find that activation of the EMT program enhances cancer cell extravasation in both of these settings. By analyzing gene expression changes associated with the EMT program, we have uncovered a mediator of the extravasation process and find that a member of the CD34 family of cell surface sialomucins, podocalyxin (PODXL), promotes extravasation and thus subsequent metastasis of cancer cells. Finally, we show that PODXL exerts its effect on extravasation by directly engaging the actin cytoskeletal linker protein ezrin to orchestrate cortical polarization in extravasating cancer cells, enabling them to initiate migration across the endothelium prior to entering the parenchyma of distant tissues.
RESULTS

Effects of EMT on Extravasation and Metastasis Formation

A mechanistic connection between the EMT program and the process of extravasation has been largely elusive. For this reason, we sought to investigate the effects of the EMT program on the ability of breast carcinoma cells to extravasate. To do so, we used immortalized, H-RAS<sup>G12V</sup>-transformed human mammary epithelial (HMLER) cells as a model system (Elenbaas et al., 2001). These cells were derived from reduction mammoplasties and exhibit epithelial traits. Although they can readily form primary tumors upon implantation in the mammary fat pad and subcutaneous sites of immunodeficient mouse hosts, the resulting tumors only rarely metastasize spontaneously to the lungs. However, upon experimental activation of the EMT program, these HMLER cells acquire stem cell-like properties and metastasize from primary tumors ((Mani et al., 2008); unpublished observations).

We first sought to directly compare the abilities of the epithelial HMLER cells and their mesenchymal derivatives to extravasate and colonize the lungs of immunocompromised mice. More specifically, we compared the behavior of parental HMLER cells with a naturally arising mesenchymal epithelial cell (NAMEC8R) population that had been previously isolated from HMLE cells and subsequently transformed by introduction of an HRAS<sup>G12V</sup> oncogene (Tam et al., 2013). These cells express many of the markers associated with the EMT program, including high levels of CD44, N-cadherin, fibronectin, vimentin, and Zeb1 (Tam et al., 2013). The parental HMLER cells, in contrast, express E-cadherin, EpCAM, and CD24. Of note, because the precursors of the more mesenchymal mammary epithelial cells had arisen spontaneously in culture, they expressed physiologic levels of various EMT-inducing transcription factors (EMT-TFs), such as Zeb1 (Tam et al., 2013).

Six weeks after injection of HMLER cells or NAMEC8Rs into the tail vein of NOD/scid IL-2R<sup>−/−</sup> (NSG) mice, bioluminescent imaging (BLI) of firefly luciferase activity revealed that only NAMEC8R, but not HMLER, cells were able to colonize the lungs of these mouse hosts (Figures 1A and 1B). Importantly, the initial numbers of HMLER and NAMEC8R cells in the lungs, measured at 10 min and 1 hr after injection, were comparable, indicating that both cell populations were trapped with comparable efficiencies in the microvessels of the lungs (Figure S1A). Accordingly, we undertook to test whether the observed failure of the HMLER cells to form metastases could be attributable to a step after trapping in microvessels but prior to colonization, more specifically, to an inability of these cells to efficiently extravasate.
To do so, we used the chick CAM assay, which represents a well-established in vivo model for extravasation (Palmer et al., 2011). Thus, we injected HMLER and NAMEC8R cells into the capillary plexus of the CAM and compared their extravasation efficiencies 24 hr post-injection. Interestingly, we found ~2.4-fold more NAMEC8R cells to have extravasated by this time point relative to the more epithelial HMLER cells (Figures 1C and 1D). This provided a direct indication of a possible involvement of the EMT program in the process of extravasation.

In order to extend these studies, we used an in vitro three-dimensional (3D) microvascular network platform specifically developed to address the process of extravasation in a highly defined experimental setting (Chen et al., 2013). To produce microvascular networks, human umbilical vein endothelial cells (HUVECs) and normal human lung fibroblasts (NHLFs) are seeded in separate channels in a fibrin hydrogel. In this setting, the suspended HUVECs form microvascular networks that allow the modeling of a variety of cell-biological processes, including the process of extravasation. We note that this experimental system only partially models the complex situation associated with the extravasation of carcinoma cells in vivo. Thus, in these in vitro microvascular networks, the cancer cells interact with endothelial cells but not with other host cell types, such as natural killer cells, platelets, and neutrophils, as they would in vivo.

These microvascular networks have been extensively characterized and exhibit tight endothelial cell-cell junctions, basement membrane deposition, and physiological values of vessel permeability (Chen et al., 2013). In this model system, the extravasation of carcinoma cells can be monitored with high spatio-temporal resolution. We tested the ability of epithelial HMLER cells and mesenchymal derivatives of this cell line to extravasate from these networks over the course of 5 hr following their introduction into the microvasculature (Videos S1 and S2). In this instance, we used both the above-described mesenchymal counterparts of the HMLER cells that had undergone an EMT spontaneously (NAMEC8R) as well as HMLER cells in which EMT had been experimentally induced through the actions of a doxycycline-inducible vector expressing either the Snail or Zeb1 EMT-TF, termed here HMLER-Snail and HMLER-Zeb1 cells (Figures S1B–S1E). Our observations revealed a modest but consistent and significant elevation (1.6- to 2-fold) of the extravasation efficiency of the various HMLER cells that had undergone an EMT relative to that of the corresponding parental HMLER cells (Figures 1E and 1F; see also Videos S1 and S2 and Figure S1F). Of note, this relative increase was comparable with the difference in extravasation efficiency that we observed in vivo in the chick CAM (Figures 1C and 1D).

Association of the EMT Program with Increased Expression of PODXL in Breast Cancer Cells

These observations prompted us to further investigate the molecular mechanisms underlying the observed elevated extravasation efficiency driven by activation of the EMT program in the HMLER cells. To begin, we tested if there were any differences in gene expression levels that could account for the observed increase in extravasation efficiency. More specifically, we used previously reported mRNA sequencing data comparing the differences in mRNA expression of the immortalized, non-RAS-transformed HMLE and NAMEC8 cells (Pattabiraman et al., 2016). This dataset revealed 256 genes to be upregulated more than 6-fold in the NAMEC8 relative to the parental HMLE cells (Figures S2A). We selected several candidate genes, focusing specifically on cell-surface proteins that might plausibly be involved in the regulation of adhesion to endothelial cells and in the transendothelial migration of these cells. Among the candidate genes we chose were those encoding the disintegrin and metalloproteinase ADAM12, ephrin type-B receptor 6 (EPHB6), PODXL, and the slit guidance ligand 2 (SLIT2) (Figure 2A).

We first examined if the difference in the mRNA expression of these candidate genes was maintained in the RAS-transformed derivatives of HMLE and NAMEC8 cells (i.e., HMLER cells and NAMEC8Rs, respectively) (Figures 2B, S2E, and S2F). The expression of two candidate genes, ADAM12 and PODXL, was also upregulated to a similar level in NAMEC8Rs relative to HMLER cells, but that of SLIT2 was not.

We next confirmed that the candidate genes listed above also exhibit elevated expression in other cell lines of the basal breast cancer subtype, which exhibit an enrichment of cells expressing certain mesenchymal markers (Sarrió et al., 2008), using a publicly available dataset (Kao et al., 2009; Figures S2B–S2D and S3A). The expression of SLIT2, ADAM12, and PODXL was upregulated 4-fold or more in many cell lines of this dataset, but that of EPHB6 was not.

Furthermore, expression of PODXL and ADAM12 mRNAs was progressively upregulated, similar to the mRNAs of well-known EMT proteins (Figures S1C and S1D), over a time course of 14 days in HMLER cells that were forced in culture to undergo an EMT through experimentally induced expression of either the SNAIL or ZEB1 EMT-TF (Figures 2C and S2G). PODXL protein expression was also upregulated in NAMEC8R relative to HMLER cells at the total-cell and cell-surface levels (Figures 2D–2G). Thus, activation of the EMT program can directly induce the expression of PODXL and ADAM12 in breast carcinoma cells. We chose to further investigate the influence of PODXL on the extravasation of cancer cells, as it has been described as a prognostic marker for breast cancer progression and metastasis (Lin et al., 2014; Somasiri et al., 2004).

Of note, PODXL was expressed in the majority of human basal breast cancer cell lines we examined (Figures S3B–S3D). Among these cell lines, highly metastatic MDA-MB-231 breast cancer cells exhibited the highest level of PODXL expression (Figures 2E and S3B–S3D). We also noted that a subclone of the MDA-MB-231 cells selected for its enhanced ability to seed lung metastases (LM2/4175 clone; Minn et al., 2005) expresses PODXL protein levels slightly higher than the corresponding parental cells (Figure S3F). This 4175 clone of the MDA-MB-231 cells also expresses all of the markers associated with an EMT to a greater extent than the parental cells and shows the spindle-shaped morphology associated with expression of an EMT program (Figures S3E and S3F).

Changes in Extravasation and Metastasis Rates of Carcinoma Cells following Loss of PODXL Expression

On the basis of these data and publications indicating the potential importance of PODXL for metastasis, we decided to examine the involvement of this protein in regulating specifically the
extravasation of breast cancer cells. Accordingly, we used CRISPR/Cas9-mediated knockout (KO) of the PODXL gene in both NAMEC8R and 4175 cells (Figures 3A, S3G, and S3H). KO of PODXL in both NAMEC8R and MDA-MB-231 4175 cells reduced their ability to extravasate from in vitro endothelial networks by a factor of 2.2-fold over a period of 5 hr (from ~20% to less than 10% of all cancer cells undergoing extravasation; Figures 3B and 3C). Importantly, this reduction in extravasation efficiency through PODXL KO is equal to the previous gain in extravasation efficiency conferred by experimental activation of the EMT program. This reduced extravasation phenotype was completely reversed by forced overexpression of a CRISPR-resistant wild-type (WT) PODXL in these cell lines, confirming the importance of PODXL for extravasation (Figures 3B and 3C). Importantly, neither KO of PODXL nor overexpression of PODXL exerted any effect either on the proliferation of NAMEC8Rs and 4175 cells in vitro (Figures S4A and S4B) or on their EMT status (Figure S4D). We did observe modest effects on the migration of NAMEC8R and MDA-MB-231 4175 cells following PODXL KO, but not on their invasiveness (Figure S3I).

We also expressed PODXL in HMLER cells that did not exhibit preexisting detectable PODXL expression (Figures 3B and 3C). The HMLER cells usually show a low baseline of extravasation over a period of 5 hr, usually involving less than 10% of all cells. Overexpression of PODXL exerted any effect either on the proliferation of NAMEC8R and 4175 cells in vitro (Figures S4A and S4B) or their EMT status (Figure S4D). We did observe modest effects on the migration of NAMEC8R and MDA-MB-231 4175 cells following PODXL KO, but not on their invasiveness (Figure S3I).

We wished to confirm that these differences in extravasation would also translate into an effect on the rate of experimental metastasis formation. For this purpose, we tested whether KO of PODXL would also lead to a decrease in lung metastasis formation by NAMEC8Rs and 4175 cells that had been injected via the tail vein (Figure 5A). Thus, we introduced via this route NAMEC8R or 4175 cells, both of which co-express a fluorescent marker and luciferase, with or without PODXL KO, into the lungs of mice and assessed tumor burden by BLI 4–6 weeks post-injection (Figures 5B and 5D). We noted that PODXL KO had no effect either on the proliferation of these cells in vitro or on primary tumor growth in vivo, arguing against an effect on their post-extravasation proliferation (Figures S4A, S4B, and S4E). In accordance with previous studies (Lin et al., 2014; Snyder et al., 2015), BLI revealed more than 2-fold and 5-fold decreases in lung metastatic burden in NAMEC8Rs and 4175 cells, respectively, with KO of PODXL (Figures 5B and 5D). The reduction in the BLI signal in the lungs of mice was also confirmed by counting the metastatic nodules (Figures 5C and 5E; see also Figures S4F and S4G). Most important, metastasis formation of the 4175 PODXL KO cell line could be rescued by re-expression of WT PODXL in these cells (Figure 5E). In light of the fact that PODXL KO had no effect on primary tumor growth and thus cell
proliferation in vivo, we favor the interpretation that the observed effect of metastasis formation was largely, if not entirely, due to an effect on extravasation.

**Functional Importance of Different Domains of PODXL for the Extravasation of Breast Carcinoma Cells**

Wishing to elucidate in more detail the molecular mechanism(s) by which PODXL could facilitate extravasation, we used a series of clones expressing mutant versions of the PODXL protein, constructed as reported previously by others (Fernández et al., 2013). Thus, we deleted from the PODXL expression vector the sequences encoding either the extracellular domain (dEC-PODXL), the entire intracellular domain (PODXL-dCD), or the relatively short DTHL signaling motif at the C terminus of the cytoplasmic domain (PODXL-dDTHL). In addition, we created as a control a fusion protein in which the extracellular domain of PODXL was replaced by the completely unrelated EGFR extracellular domain (EGFR-PODXL). Relevant to later experiments, all of the mutant PODXL clones were constructed to be resistant to constitutively expressed Cas9/sg4. We then expressed these PODXL mutants in the NAMEC8R cells and in the 4175 cells with KO of PODXL (Figures 6A and S6A–S6D).

We proceeded to study the effects of these various PODXL mutants on the extravasation efficiency of NAMEC8R and 4175 cells using the in vitro microvascular networks to do so. Interestingly, NAMEC8R and 4175 PODXL KO cells expressing PODXL mutants carrying either a deletion of the entire extracellular domain (dEC-PODXL) or the DTHL signaling motif or expressing an EGFR-PODXL fusion protein regained a rate of extravasation comparable with the level observed with control cells that had not undergone PODXL KO (Figures 6B and 6C). Only expression of the PODXL mutant carrying a deletion of the entire intracellular domain (PODXL-dCD) failed to rescue the effect that loss of PODXL had on the extravasation of NAMEC8R and 4175 cells.
This allowed us to conclude that the intracellular domain, but not the C-terminal DTHL signaling motif or the ectodomain, is required for extravasation.

Two types of proteins have been repeatedly shown to directly interact with the cytoplasmic domain of PODXL: NHERF1/2 and ezrin (Nielsen and McNagny, 2009; Schmieder et al., 2004; Sizemore et al., 2007). The DTHL signaling motif in the cytoplasmic tail of PODXL is required for its interaction with the NHERF1/2 proteins. In contrast, ezrin can interact with PODXL both indirectly through NHERF1/2 and directly by binding to the PODXL juxtamembrane domain. Interestingly, ezrin has previously been indicated as an important regulator of breast cancer metastasis (Elliott et al., 2005). For this reason, we determined whether loss of ezrin could phenocopy the loss of PODXL in the in vitro extravasation model. Indeed, knockdown (KD) of ezrin also led to a marked decrease in the extravasation efficiency (1.7- and 3.9-fold) from microvascular networks (Figures 6D and 6E).

We also wished to further confirm that the observed effect on extravasation was indeed mediated through the PODXL-ezrin signaling axis. A previous study showed that 95% of the PODXL-ezrin physical interaction could be abolished by mutating three amino acids (H-R-S) in the juxtamembrane domain of PODXL that are required for direct interaction with ezrin (PODXL-HRS/AAA mutant) (Schmieder et al., 2004). Indeed, expression of the PODXL-HRS/AAA mutant in PODXL KO cells was unable to rescue the defect in extravasation caused by loss of WT PODXL (Figures 6B and 6C). Because ezrin is the only protein to date that has been described to directly interact with PODXL through this amino acid motif (Schmieder et al., 2004), we concluded that the extravasation of breast cancer cells is determined by a PODXL-ezrin signaling axis that is dependent on the direct binding of ezrin to the juxtamembrane domain of PODXL.

Role of PODXL and Ezrin in Dorsal Cortical Polarization during Extravasation

In the general circulation, individual cancer cells adopt a symmetric, round morphology (Reymond et al., 2013). During extravasation, however, cancer cells must respond to adhesive conditions that impart physical asymmetries, which in turn leads to major rearrangements of the actin cytoskeleton and an uneven, or polarized, distribution of proteins within the cell (Miles et al., 2008; Reymond et al., 2013). Members of the highly homologous ERM protein family, consisting of ezrin, radixin, and moesin, provide linkage between plasma membrane proteins, such as PODXL, and the cortical actin cytoskeleton (i.e., the cytoskeleton underlying the plasma membrane); these ERM proteins are therefore key regulators of changes in cell morphology and polarity (Fehon et al., 2010). Indeed, a recent study reported that the ERM protein moesin is necessary for the reorganization of cortical actin during transendothelial migration and invasion in melanoma cells (Estecha et al., 2009). We hypothesized that ezrin, much like moesin, might be important for the cytoskeletal reorganization occurring during extravasation in carcinoma cells.

We therefore set out to visualize the intracellular distribution of ezrin during transendothelial migration through HUVEC monolayers seeded on top of 3D collagen matrices, as described previously (Estecha et al., 2009). For this purpose, we used NAMEC8R cells with or without PODXL KO expressing Par1b-Clover. Par1b is a protein kinase that is involved in the establishment and maintenance of cell polarity in various biological contexts and functions antagonistically to the atypical protein kinase C (aPKC)/Par3/Par6 complex (Benton and St Johnston, 2003). The Par1b-Clover was used as a reporter to indicate the establishment of polarity during extravasation. We allowed the carcinoma cells to interact with endothelial cells for 3 hr and then fixed and stained for ezrin. Echoing the results of previous experimental methods that we had used to measure extravasation, NAMEC8R cells with PODXL KO were 3-fold less efficient in...
completing endothelial transmigration than the parental cells in this assay (Figure 6G).

We observed that most of the ezrin protein was redistributed away from the region of adhesion to endothelial cells (ventral side) and instead formed a cap-like structure at the unattached cell cortex (dorsal side) in all extravasating cells examined (Figures 6F and 6H). PODXL was colocalized with ezrin in this cap-like structure (Figure S6E). Additionally, a small proportion of ezrin was present at the very tips of the invasive foot processes at the ventral side. In contrast, Par1b was redistributed to the invasive foot processes of these cells, away from the dorsal cortex and thus in close apposition to the endothelial cells. All carcinoma cells that failed to extravasate remained rounded, and indeed ezrin and Par1b remained evenly distributed around and beneath the plasma membrane of these cells (Figure 6F). This suggests that breast cancer cells use a PODXL-ezrin signaling axis in order to undergo the cytoskeletal rearrangements and cell polarization required for extravasation.

DISCUSSION

One of the many challenges that disseminated circulating cancer cells must confront in order to successfully serve as founders of metastatic colonies is created by the hostile intravascular environment, dictating that these cells must escape as quickly as possible from this environment via extravasation into the parenchyma of surrounding tissues (Reymond et al., 2013). Although this process has been studied in great detail in the context of leukocytes diapedesis, comparatively little is known about the corresponding mechanisms in carcinoma cells (Strell and Entschladen, 2008). Others previously showed that melanoma cells expressing the Twist EMT-TF became more efficient at extravasation in a zebrafish model, doing so through unknown mechanisms (Stoletov et al., 2010).

In the present study, we demonstrate that activation of the EMT program by various EMT-TFs directly regulates the extravasation efficiency and subsequent metastasis of breast carcinoma cells by upregulating the expression of the cell-surface protein PODXL. Another study showing the upregulation of PODXL during EMT in lung cancer cells pointed to the possibility of PODXL induction by EMT in a variety of cancer types without indicating the mechanistic role that this protein played in metastasis formation (Meng et al., 2011). Indeed, we could confirm the EMT-induced upregulation of PODXL in breast cancer cells as well as its high expression levels in more mesenchymal pancreatic cancer cell lines relative to an epithelial pancreatic cancer cell line.

Of note, over the past decade this protein has repeatedly emerged as a predictor of poor prognosis and distant metastasis in many carcinoma types (Laitinen et al., 2015; Larsson et al., 2011; Nielsen and McNagny, 2009; Saukkonen et al., 2015; Somasiri et al., 2004). Nevertheless, its precise mechanisms of action have remained largely elusive. Two studies using short hairpin RNA (shRNA)-mediated KD of PODXL in breast cancer cell lines have demonstrated that it functions as an important
Figure 6. Interaction of PODXL and Ezrin via the Juxtamembrane Domain of PODXL and Establishment of Cortical Polarization Associated with Extravasation

(A) Design of PODXL mutants.
(B and C) Extravasation efficiency of cells of the (B) NAMEC8R and (C) 4175 cell lines expressing either WT PODXL or different PODXL mutants. Deletion of the intracellular domain of PODXL (PODXL-dCD) and mutation of the ezrin-binding site (PODXL-HRS/AAA) mimic PODXL KO phenotype. Data were collected from at least three independent experiments, using three devices per condition and experiment.
(D) shRNA-mediated knockdown of ezrin in MDA-MB-231 4175 cells on the protein levels as shown by western blot analysis.

(legend continued on next page)
mediator of metastasis, doing so without revealing the precise steps of the invasion-metastasis cascade that this protein affected (Lin et al., 2014; Snyder et al., 2015). In the present studies of the precise mechanism of action of PODXL, we show that KO of PODXL specifically inhibits the extravasation of breast carcinoma cells, that this correlates with reduced metastasis formation in vivo, and that this effect can be rescued by re-expressing WT PODXL.

The extracellular domain of PODXL has been shown to act as a ligand for selectins, including E-selectin expressed by endothelial cells (Dallas et al., 2012; Larrucea et al., 2007). Unexpectedly, we describe the fact that the effect of PODXL on extravasation is not dependent on the heavily glycosylated ectodomain but instead on the direct interaction of its juxtamembrane domain with the ERM protein ezrin, another well-known mediator of metastasis (Elliott et al., 2005; Khanna et al., 2004; Meng et al., 2010); this was demonstrated both by deleting the ectodomain of PODXL and by replacing it with the ectodomain of an unrelated cell-surface protein, that of the EGF receptor. We found this most surprising, because many transmembrane proteins use their extracellular domains to acquire signals from other cells or from the extracellular matrix.

Our study focused on metastasis to the lung, a tissue whose endothelial cells are known to express very low levels of E-selectin, a key ligand of PODXL (Dallas et al., 2012; Strell and Entschladen, 2008). Circulating carcinoma cells may not require E-selectin in order to arrest in the lung tissue, as the luminal diameters of the endothelial capillaries are small and favor physical trapping of cancer cells (Miles et al., 2008; Reymond et al., 2013). As such, it remains to be seen if the mechanism of extravasation we uncovered is unique to the lung or can be extended to other organs.

The extravasation advantage conferred on breast and pancreatic cancer cells by activation of the EMT program was almost entirely eliminated with the loss of PODXL. Nonetheless, we observed relatively low amounts of ~10% absolute extravasation in HMLER cells and carcinoma cells with PODXL KO in vitro. This residual extravasation may be explained by alternative mechanisms of extravasation that have been described to date, such as angiopellosis, a mechanism of extravasation that is orchestrated by endothelial cells, by necroptosis, or by other molecules expressed on cancer cells, such as amyloid precursor protein (APP) or angiopetin-like 4 (ANGPTL4) (Allen et al., 2017; Huang et al., 2011; Kanada et al., 2014; Padua et al., 2008; Strilic et al., 2016). Furthermore, additional cell types, such as natural killer cells, leukocytes, and platelets, can modulate this process in vivo by improving cancer cell resistance to shear stress, protecting cancer cells from the immune system, or increasing cancer cell binding to the endothelium (Reymond et al., 2013). How these factors might affect the extravasation of PODXL-expressing cancer cells remains to be studied.

The PODXL-ezrin interaction, achieved either directly or indirectly via NHERF1/2, has been previously described and suggested to regulate cancer cell traits associated with aggressiveness, such as migration and invasion in vitro (Lin et al., 2014; Sizemore et al., 2007). We find that deletion of PODXL as well as disruption of PODXL-ezrin interaction leads to a failure of breast cancer cells to initiate extravasation, which requires extensive cytoskeletal remodeling and the transient establishment of cell polarity (Miles et al., 2008; Reymond et al., 2013). Both PODXL and ezrin have been previously shown to function as polarity proteins that are involved in organizing apical-basal polarity and lumen formation (Orlando et al., 2001; Schneider et al., 2004). ERM proteins generally play a key role as mediators between transmembrane proteins, such as PODXL, and the F-actin cytoskeleton, and a recent study showed that moesin, an ERM family member, was crucial in mediating invasion and transendothelial migration in melanoma cells in vitro by establishing cortical polarization away from the region of cell attachment (Estecha et al., 2009). We find that during extravasation of PODXL-expressing breast cancer cells, the ERM family member ezrin becomes redistributed to a cap-like structure at the dorsal cortex away from the side of attachment to endothelial cells, where it co-localizes with PODXL. In contrast, we observed that cancer cells that had lost PODXL generally failed to redistribute ezrin to a specific location, remained rounded inside the vasculature, and failed to extravasate.

The EMT program has previously been implicated in contributing to completion of many steps of the invasion-metastasis cascade. Here we have uncovered a way in which this program can act during tumor cell dissemination by inducing a PODXL-ezrin signaling axis that enables the dynamic cytoskeletal rearrangements necessary for transendothelial migration.

**EXPERIMENTAL PROCEDURES**

**Cell Lines and Cell Culture**

HMLER (Elenbaas et al., 2001), NAMEC8R and HMLER-Snail (Tam et al., 2013), HMLER-Zeb1 (Pattabiraman et al., 2016) and LM2-MDA-MB-231 (clone 4175; Minn et al., 2005), NCICIT (cells were a gift from CureMeta, BxPC3, MiaPaca2, and Panc1 cells were used in this study. BxPC3 and MiaPaca2 cells were a gift from R. Hynes. Panc1 cells were obtained from the American Type Culture Collection (ATCC). HMLER cells and their derivatives were maintained in MEGM media as previously described (Elenbaas et al., 2001). Clone 4175 cells and pancreatic cell lines were maintained in DME with 10% fetal bovine...
RNA-seq data reported in this paper is GEO: GSE74883. For the identification of cell-surface proteins differentially expressed in cells was analyzed (Pattabiraman et al., 2016). The accession number for the Microfluidic Networks for Extravasation Assays

All extravasation assays in microvascular networks in vitro were prepared and seeded according to a published protocol (Chen et al., 2017). Cancer cells were prepared at a concentration of 5 × 10^5 cells/mL in EGM-2, and 40–50 µL was perfused into each network. Subsequently, microfluidic devices were incubated for 5 hr at 37°C under static conditions, with 5% CO2 and then fixed using 4% paraformaldehyde (PFA). Extravasated cells were quantified using an Olympus FV1000 confocal microscope. Multiple z stacks were acquired at 20X magnification per imaged sample using an LSM710 confocal microscope (Zeiss) and analyzed using Imaris software.

Cancer Cell Migration through HUVEC Monolayers Cultured on Collagen I Gels

Collagen gel matrices were prepared as previously described (Artym and Matsumoto, 2010). Subsequently, HUVEC-Azurite were seeded on top of the polymerized collagen gels in 200 µL EGM-2 (2 × 10^5 cells/mL) and grown to confluence before cancer cells were seeded sparsely (0.5 × 10^5 cell/well) on top of the monolayers. Z stacks were obtained at multiple positions (two or three) at 63X magnification per imaged section using an LSM710 confocal microscope (Zeiss) and analyzed using Imaaris software.

CAM Assay

In order to study the extravasation of cancer cells in vivo, the CAM of the chick embryo was used as described previously (Palmer et al., 2011). In brief, 1 × 10^5 cancer cells per chick were directly injected into the allantoic vein, and the eggs were incubated for 24 hr. Three sections of CAM with a 1 cm radius were harvested per chick embryo. Extravasated cells were imaged using a Zeiss Lumar StereoScope at 50X. Per experimental group, two or three chicks were analyzed. Five random fields of view were imaged per section of CAM. The number of extravasated cancer cells per field was quantified using ImageJ (NIH).

Cancer Cell Injection into Mice

Animal studies were conducted following the MIT Committee on Animal Care protocol (protocol number 1017-097-20). For primary tumor formation, 2 × 10^3 NAMEC8R/HMLER cells were injected into 8-week-old male Nod/Scid and NSG mice, respectively. Lung metastases were monitored via bioluminescence in live animals using the IVIS Spectrum in vivo imaging system. Images were analyzed using Living Image software (PerkinElmer).

The lungs of NSG mice injected with HMLER or NAMEC8R cells were also checked for metastases using the M212 Stereomicroscope (Leica). Metastases were quantified by counting tdTomato-fluorescent tumor nodules (HMLER/NAMC8R) or by H&E staining (4175). For higher accuracy, five H&E sections in 50 µm increments were quantified for each mouse and averaged.

Statistical Analysis

All statistics were calculated using GraphPad Prism, either using the Mann-Whitney U test or Student’s t test as detailed in the figure legends.

DATA AND SOFTWARE AVAILABILITY

For the identification of cell-surface proteins differentially expressed in cells prior to and after an EMT, a previously published mRNA sequencing dataset was analyzed (Pattabiraman et al., 2016). The accession number for the RNA-seq data reported in this paper is GEO: GSE74883.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and two videos and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.06.092.

ACKNOWLEDGMENTS

We would like to thank A. Lambert, T. Shibue, W. Henry, and J. Krall for their critical review of the manuscript; P. Thiru from BARC for his help with the bioinformatic analyses; CureMeta for PODXL antibodies; A. McClatchey for discussions; B. Bierie, C. Kroeger, Z. Maimaiti, V. Liu, K. Xu, and T. Shibue for experimental assistance; the whole Weinberg laboratory for discussions and reagents; the Whitehead Institute microscope and flow cytometry core facilities; and the Koch Institute small animal imaging core and histology core facility. R.A.W. is an American Cancer Society Research Professor and a Daniel K. Ludwig Cancer Research Professor. J.F., F.R., and R.A.W. received support from the NIH (grant R01 CA078461) and CureMeta. M.B.C., C.H., and R.D.K. were supported by the National Cancer Institute (grant U01 CA202177). A.Z. was supported by NIH/NCI grant R01CA218526. K.E.H. was supported by the Microenvironmental Influences in Cancer Training Program (NIH/NCI grant 1F31CA189764-03). R.D.K. is a founder of AIM Biotech and a member of its board.

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

Received: February 28, 2018

Revised: May 29, 2018

Accepted: June 21, 2018

Published: July 24, 2018

REFERENCES


